- contact@amcs.at
The Austrian Multiple Sclerosis Cohort (AMSC) has been recruiting patients with multiple sclerosis (MS) from specialized centers across Austria since 2023. Its primary objective is to generate high-quality data to support high-level clinical research in the field of MS, with the aim of further advancing both diagnostic approaches and individualized therapeutic strategies. In the long term, the cohort seeks to translate new scientific insights into routine clinical practice and thereby improve the care of people living with MS.
Patient data, e.g. demographic and socioeconomic data, are assessed every 6 to 12 months.
Clinical examinations are performed by experienced certified clinicians every 6 to 12 months.
Paraclinical data includes MRI and OCT scans (every 12 to 24 months), as well as blood (every 6 to 12 months) and CSF samples (at baseline).
Data of disease modifying treatments (DMT) and symptomatic therapies is assessed every 6 to 12 months.
The Austrian Multiple Sclerosis Cohort (AMSC) is supported by the Austrian Multiple Sclerosis Innovation Alliance (AMSIA). AMSIA is a consortium of experts dedicated to promoting and advancing multiple sclerosis research in Austria. It supports important real-world MS research projects, fosters collaboration among specialists, and contributes to raising public awareness of MS. The overarching goal is to improve both the medical care and the quality of life of people living with MS.